GSK plc
UK based pharma giant selling vaccines and specialty medicines including HIV drugs worldwide.
On the record
Checkpoint: Q4M PrEP long acting HIV readout and FDA decision on bepirovirsen for hepatitis B
The call
GSK's size and drug approvals hold it steady for years, while the real test is whether new HIV shots and cancer drugs can replace the sales it loses when dolutegravir goes generic.
GSK makes prescription medicines and vaccines sold worldwide. Its biggest risk is losing patent protection on dolutegravir, an HIV drug worth about £4 billion annually, around 2028 to 2030. GSK is already preparing by developing long-acting HIV shots like Cabenuva and Apretude, which could replace the lost sales, but whether these newer drugs grow fast enough to fill the gap will determine if the company stays flat or bounces back stronger. Competitors like Gilead have rival HIV drugs, but neither company can be quickly replaced because making approved medicines requires years of testing and regulatory approval that AI alone cannot skip.
Why
01
AI pressure: None apparent. AI tools speed up GSK's own drug discovery and trial design, they do not replace regulated medicines or take patients away. Could AI do the core job? Unlikely.
02
Bigger players: Gilead Sciences. Gilead's Biktarvy and Sunlenca fight GSK drug by drug in HIV, and generics will hit GSK's dolutegravir franchise from 2028. Could a giant copy it? No, they are blocked.
03
What protects it. Regulatory approvals, manufacturing scale, and a switch to long acting HIV shots that are hard to copy fast.
What would change this call
Q2 2026 earnings (~28 July 2026) show HIV segment growth trend. Indicates whether long-acting injectables are offsetting Gilead's competitive pressure.
Bepirovirsen FDA decision, October 2026. Shows whether GSK's pipeline rebuild is delivering new approvals beyond HIV.
Dolutegravir generic entry timing between 2028 and 2030. Tests whether the ~£4bn HIV patent cliff exposure materializes on schedule.
Bepirovirsen FDA decision, October 2026. Shows whether GSK's pipeline rebuild is delivering new approvals beyond HIV.
Dolutegravir generic entry timing between 2028 and 2030. Tests whether the ~£4bn HIV patent cliff exposure materializes on schedule.
Key numbers
- £32.7B revenue, up 7% at constant currency
- About £4B HIV sales at risk from 2028 to 2030
- 66,841 employees, down 2.6% year over year
Named risks
- Dolutegravir HIV patent cliff 2028-2030 threatens roughly £4 billion in sales.
- Camlipixant Phase III failure in July 2026 removed a 2031 growth plan asset.
- Residual Zantac federal MDL litigation with hundreds of pending cases and unapproved $70M qui tam settlement.
- New CEO Luke Miels faces execution risk on £40B 2031 sales ambition amid patent cliffs.
- Divergent third-party headcount estimates create uncertainty around workforce trend.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Gilead Sciences | losing to | Biktarvy and Sunlenca compete directly against GSK's dolutegravir-based HIV franchise, as of May 2026 |
| AstraZeneca | contesting | Larger UK pharma peer with roughly $325B market cap versus GSK's $122.6B, as of Feb 2026 |
| J&J, Pfizer, Regeneron, BMS | contesting | BCMA-targeted myeloma therapies (Carvykti, Elrexfio, Lynozyfic, Abecma) compete with GSK's re-approved Blenrep as of Oct 2025 |
| Sanofi, Pfizer, Merck | contesting | Vaccine market rivals competing with GSK's Shingrix and Arexvy franchises |
Questions people ask
- Is GSK profitable in 2026?
- Yes. GSK reported FY2025 group turnover of £32.7 billion, up 7% at constant exchange rates, with core operating profit up 11% and core EPS up 12%, per its February 3, 2026 results release. FY2026 guidance projects further 7-9% core EPS growth.
- Could AI replace GSK?
- No. GSK uses AI as a research tool, not a substitute for its core business. It licensed Noetik's spatial AI models for oncology (January 8, 2026, $50M upfront) and partnered with Imperial's Fleming Initiative on AMR AI (November 2025), but regulatory approval and manufacturing remain the real moat.
- Who is GSK's biggest competitor?
- In HIV, Gilead Sciences is GSK's closest rival, with Biktarvy and Sunlenca competing against GSK's dolutegravir-based Cabenuva and Apretude franchise, per a May 26, 2026 Yahoo Finance analysis. AstraZeneca, a larger UK pharma peer, is also a broad competitor.
- Who owns GSK?
- GSK plc is a publicly traded company with no controlling parent, listed primarily on the London Stock Exchange and secondarily on the NYSE. Its market capitalization was cited at $122.6 billion as of February 2026, per Wikipedia.
- What happened to GSK's chronic cough drug camlipixant?
- GSK halted development of camlipixant in July 2026 after a Phase III trial miss, cutting a piece of its 2031 growth plan and sending shares down about 4%, according to an Economic Times Pharma report dated July 17, 2026.
- How exposed is GSK to the HIV patent cliff?
- Analysts flag roughly £4 billion in sales-decline risk from 2030 tied to the dolutegravir patent cliff running 2028-2030, per a Morningstar report dated July 10, 2026. GSK is hedging this via long-acting injectables Cabenuva and Apretude, which already drive over 75% of HIV segment growth.
Timeline
- 2026-07-17GSK halts camlipixant chronic cough drug after Phase III miss; shares fall ~4%
- 2026-07-15GSK completes $10.6B Nuvalent acquisition adding lung-cancer assets
- 2026-07-13Roy Jakobs joins GSK board as Non-Executive Director
- 2026-06-30Blenrep assigned permanent CMS billing code effective July 1, 2026
- 2026-02-03GSK reports FY2025 turnover of £32.7B, up 7% CER, issues FY2026 guidance
- 2026-01-08GSK signs $50M, five-year AI licensing deal with Noetik for oncology
- 2026-01-01Luke Miels becomes GSK CEO, succeeding Emma Walmsley
- 2025-11-17GSK launches £45M AI antimicrobial-resistance partnership with Imperial's Fleming Initiative
- 2025-10-23FDA re-approves Blenrep (belantamab mafodotin) for multiple myeloma
- 2025-09-29Luke Miels appointed CEO Designate of GSK
Revision history
20 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- GSK delivers strong 2025 performance and re-affirms long-term outlooks (2026-02-03)
- GSK Financials & Income Statement (2026-07-14)
- GSK Q2 2026 Earnings Preview (2026-07-09)
- GSK: Comeback? (2026-07-10)
- GSK plc Number of Employees 1998-2025 (2026-06-01)
- GSK plc (2026-07-17)
- Luke Miels appointed CEO Designate for GSK (2025-09-29)
- FDA Approves Belantamab Mafodotin (BLMF) for Relapsed or Refractory Multiple Myeloma (2025-10-22)
- GSK stops development of chronic cough drug after late-stage trial miss (2026-07-17)
- GSK completes acquisition of Nuvalent, Inc. (2026-07-15)
- Statement: Zantac (Ranitidine) litigation settlement agreements reached (2024-10-09)
- AI Foundation Models in Pharma: GSK-Noetik (2026-07-09)